Jeremy B Graff

US Patent:

20210283169, Sep 16, 2021

Filed:

Mar 29, 2021

Appl. No.:

17/215195

Inventors:

- New York NY, US
Keith Gorden - Woodberry MN, US
Anissa SH. Chan - Arden Hills MN, US
Steven Leonardo - Rosemount MN, US
Jeremy Graff - Indianapolis IN, US
Xiaohong Qiu - Edina MN, US
Takashi Kangas - Shoreview MN, US
Kathryn A. Fraser - St. Paul MN, US
Adria Bykowski Jonas - Eden Prairie MN, US
Nadine Ottoson - Lakeville MN, US
Ross Fulton - St. Paul MN, US

International Classification:

A61K 31/716
C12N 5/0783
A61K 39/395
C07K 16/28
C12N 5/0784
C12N 5/0786
C07K 16/30

Abstract:

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

US Patent:

20200033362, Jan 30, 2020

Filed:

Feb 23, 2018

Appl. No.:

16/488911

Inventors:

- Eagan MN, US
Nadine OTTOSON - Lakeville MN, US
Ben HARRISON - Eagan MN, US
Jamie LOWE - Woodbury MN, US
Mark UHLIK - Indianapolis IN, US
Jeremy GRAFF - Indianapolis IN, US
Richard HUHN - St. Paul MN, US

Assignee:

BIOTHERA PHARMACEUTICALS, INC. - Eagan MN

International Classification:

G01N 33/68
A61K 31/716

Abstract:

This disclosure provides, in one aspect, dosing strategies for soluble β-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble β-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-β-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

US Patent:

20190060350, Feb 28, 2019

Filed:

Oct 29, 2018

Appl. No.:

16/174157

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Anissa SH. CHAN - Arden Hills MN, US
Steven LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US
Xiaohong QIU - Edina MN, US
Takashi KANGAS - Shoreview MN, US
Kathryn A. FRASER - St. Paul MN, US
Adria BYKOWSKI JONAS - Eden Prairie MN, US
Nadine OTTOSON - Lakeville MN, US
Ross FULTON - St. Paul MN, US

International Classification:

A61K 31/716
C07K 16/30
A61K 39/395
C12N 5/0783
C07K 16/28

Abstract:

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

US Patent:

20190060351, Feb 28, 2019

Filed:

Oct 29, 2018

Appl. No.:

16/174177

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Anissa SH. CHAN - Arden Hills MN, US
Steven LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US
Xiaohong QIU - Edina MN, US
Takashi KANGAS - Shoreview MN, US
Kathryn A. FRASER - St. Paul MN, US
Adria BYKOWSKI JONAS - Eden Prairie MN, US
Nadine OTTOSON - Lakeville MN, US
Ross FULTON - St. Paul MN, US

International Classification:

A61K 31/716
C07K 16/30
C07K 16/22
C07K 16/28
A61K 45/06
A61K 9/00
C07K 16/44
A61K 39/395

Abstract:

The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

US Patent:

20190022129, Jan 24, 2019

Filed:

Jan 9, 2017

Appl. No.:

16/068868

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Ross FULTON - St. Paul MN, US
Steve LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US

International Classification:

A61K 31/716
C07K 16/28
A61K 39/395
A61P 35/00

Abstract:

This disclosure relates to soluble β-glucan immunotherapies that affect the tumor microenvironment. The soluble β-glucan immunotherapies promote an immunostimulatory environment, which enhances the effectiveness of the combination of anti-angiogenics and checkpoint inhibitors.

US Patent:

20170100424, Apr 13, 2017

Filed:

Dec 21, 2016

Appl. No.:

15/386781

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Anissa SH. CHAN - Arden Hills MN, US
Steven LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US
Xiaohong QIU - Edina MN, US
Takashi KANGAS - Shoreview MN, US
Kathryn A. FRASER - St. Paul MN, US
Adria BYKOWSKI JONAS - Eden Prairie MN, US
Nadine OTTOSON - Lakeville MN, US

International Classification:

A61K 31/716
C07K 16/30
A61K 39/395
C07K 16/28

Abstract:

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

US Patent:

20170100425, Apr 13, 2017

Filed:

Dec 21, 2016

Appl. No.:

15/386887

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Anissa SH. CHAN - Arden Hills MN, US
Steven LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US
Xiaohong QIU - Edina MN, US
Takashi KANGAS - Shoreview MN, US
Kathryn A. FRASER - St. Paul MN, US
Adria BYKOWSKI JONAS - Eden Prairie MN, US
Nadine OTTOSON - Lakeville MN, US

International Classification:

A61K 31/716
A61K 39/395
A61K 9/00
C07K 16/44
C07K 16/28
C07K 16/30

Abstract:

The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.